Business Context and Reporting Period
Company: Pluristem Therapeutics Inc. (PSTI)
Filing Type: Form 8-K (Current Report)
Report Date: February 3, 2021 (Event Date: February 2, 2021)
Context: The Company announced the entry into a Material Definitive Agreement for a registered direct offering of common stock to institutional investors.
Key Financial Metrics
This filing details a capital raise event rather than periodic financial performance. Specific metrics include:
- Shares Issued: 4,761,905 shares of common stock.
- Price Per Share: $6.30.
- Gross Proceeds: Approximately $30 million.
- Placement Fee: 6% of aggregate gross proceeds paid to A.G.P./Alliance Global Partners.
- Use of Proceeds: Working capital.
Note: The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The primary material change is the execution of a Securities Purchase Agreement on February 2, 2021, authorizing the sale of equity securities. The closing of the offering was expected to occur on February 4, 2021, subject to customary conditions.
Guidance, Outlook, and Restrictions
Management Commentary: The Company intends to utilize net proceeds for working capital purposes. The offering is conducted under an existing shelf registration statement (Form S-3) declared effective on July 23, 2020.
Lock-Up Provisions:
- Open Market Sales Agreement: Prohibited for 45 days from closing.
- Issuance of Securities: Prohibited for 60 days from closing (including convertible or exercisable securities) without prior written consent from placement agents or investors, subject to specific exceptions.
Risks and Contingencies: The closing is subject to customary conditions. The filing explicitly states that representations and warranties are made solely for the benefit of the parties to the agreements and are qualified by reference to the full text of the agreements filed as exhibits.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected February 4, 2021) and confirmation of fund receipt.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Placement Agency Agreement (Exhibit 10.2) for specific covenants and exceptions to the lock-up period.
- Confirm the impact of the 4,761,905 new shares on existing shareholder dilution.
- Monitor subsequent filings for the actual net proceeds after deduction of the 6% placement fee and other offering expenses.